Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 245

1.

Changes in body composition and muscle attenuation during taxane-based chemotherapy in patients with metastatic breast cancer.

Rier HN, Jager A, Sleijfer S, van Rosmalen J, Kock MCJM, Levin MD.

Breast Cancer Res Treat. 2017 Nov 17. doi: 10.1007/s10549-017-4574-0. [Epub ahead of print]

PMID:
29147870
2.

Breast cancer genomics and immuno-oncological markers to guide immune therapies.

Hammerl D, Smid M, Timmermans AM, Sleijfer S, Martens JWM, Debets R.

Semin Cancer Biol. 2017 Nov 6. pii: S1044-579X(17)30186-4. doi: 10.1016/j.semcancer.2017.11.003. [Epub ahead of print] Review.

3.

Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients.

Beije N, Sieuwerts AM, Kraan J, Van NM, Onstenk W, Vitale SR, van der Vlugt-Daane M, Dirix LY, Brouwer A, Hamberg P, de Jongh FE, Jager A, Seynaeve CM, Jansen MPHM, Foekens JA, Martens JWM, Sleijfer S.

Mol Oncol. 2017 Oct 24. doi: 10.1002/1878-0261.12147. [Epub ahead of print]

4.

Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib.

Verboom MC, Kloth JSL, Swen JJ, van der Straaten T, Bovée JVMG, Sleijfer S, Reyners AKL, Mathijssen RHJ, Guchelaar HJ, Steeghs N, Gelderblom H.

Eur J Cancer. 2017 Nov;86:226-232. doi: 10.1016/j.ejca.2017.09.025. Epub 2017 Oct 18.

PMID:
29054076
5.

Molecular Tumor Boards: Current Practice and Future Needs.

van der Velden DL, van Herpen CML, van Laarhoven HWM, Smit EF, Groen HJM, Willems SM, Nederlof PM, Langenberg MHG, Cuppen E, Sleijfer S, Steeghs N, Voest EE.

Ann Oncol. 2017 Sep 27. doi: 10.1093/annonc/mdx528. [Epub ahead of print]

PMID:
29045504
6.

Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma.

de Groot S, Redekop WK, Versteegh MM, Sleijfer S, Oosterwijk E, Kiemeney LALM, Uyl-de Groot CA.

Qual Life Res. 2017 Sep 15. doi: 10.1007/s11136-017-1704-4. [Epub ahead of print]

PMID:
28917029
7.

Predicting clinical benefit from everolimus in patients with advanced solid tumors, the CPCT-03 study.

Weeber F, Cirkel GA, Hoogstraat M, Bins S, Gadellaa-van Hooijdonk CGM, Ooft S, van Werkhoven E, Willems SM, van Stralen M, Veldhuis WB, Besselink NJM, Horlings HM, Steeghs N, de Jonge MJ, Langenberg MHG, Wessels LFA, Cuppen EPJG, Schellens JH, Sleijfer S, Lolkema MP, Voest EE.

Oncotarget. 2017 Mar 8;8(33):55582-55592. doi: 10.18632/oncotarget.16029. eCollection 2017 Aug 15.

8.

Expression and inhibition of BRD4, EZH2 and TOP2A in neurofibromas and malignant peripheral nerve sheath tumors.

Amirnasr A, Verdijk RM, van Kuijk PF, Taal W, Sleijfer S, Wiemer EAC.

PLoS One. 2017 Aug 15;12(8):e0183155. doi: 10.1371/journal.pone.0183155. eCollection 2017.

9.

Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity.

Meulendijks D, Jacob W, Voest EE, Mau-Sorensen M, Martinez-Garcia M, Taus A, Fleitas T, Cervantes A, Lolkema MP, Langenberg MHG, De Jonge MJ, Sleijfer S, Han JY, Calles A, Felip E, Kim SW, Schellens JHM, Wilson S, Thomas M, Ceppi M, Meneses-Lorente G, James I, Vega-Harring S, Dua R, Nguyen M, Steiner L, Adessi C, Michielin F, Bossenmaier B, Weisser M, Lassen UN.

Clin Cancer Res. 2017 Sep 15;23(18):5406-5415. doi: 10.1158/1078-0432.CCR-17-0812. Epub 2017 Jun 9.

PMID:
28600476
10.

Improved diagnosis and prognostication of patients with pleural malignant mesothelioma using biomarkers in pleural effusions and peripheral blood samples - a short report.

Beije N, Kraan J, den Bakker MA, Maat APWM, van der Leest C, Cornelissen R, Van NM, Martens JWM, Aerts JGJV, Sleijfer S.

Cell Oncol (Dordr). 2017 Oct;40(5):511-519. doi: 10.1007/s13402-017-0327-7. Epub 2017 Jun 2.

11.

First-Line Palliative HER2-Targeted Therapy in HER2-Positive Metastatic Breast Cancer Is Less Effective After Previous Adjuvant Trastuzumab-Based Therapy.

Rier HN, Levin MD, van Rosmalen J, Bos MMEM, Drooger JC, de Jong P, Portielje JEA, Elsten EMP, Ten Tije AJ, Sleijfer S, Jager A.

Oncologist. 2017 Aug;22(8):901-909. doi: 10.1634/theoncologist.2016-0448. Epub 2017 May 22.

PMID:
28533475
12.

Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments.

De Groot S, Blommestein HM, Redekop WK, Sleijfer S, Kiemeney LALM, Oosterwijk E, Uyl-de Groot CA.

PLoS One. 2017 May 22;12(5):e0177364. doi: 10.1371/journal.pone.0177364. eCollection 2017.

13.

Somatic Tumor Mutations Detected by Targeted Next Generation Sequencing in Minute Amounts of Serum-Derived Cell-Free DNA.

Weerts MJA, van Marion R, Helmijr JCA, Beaufort CM, Krol NMG, Trapman-Jansen AMAC, Dinjens WNM, Sleijfer S, Jansen MPHM, Martens JWM.

Sci Rep. 2017 May 18;7(1):2136. doi: 10.1038/s41598-017-02388-7.

14.

Tumor cell expression of immune inhibitory molecules and tumor-infiltrating lymphocyte count predict cancer-specific survival in pancreatic and ampullary cancer.

Sideras K, Biermann K, Yap K, Mancham S, Boor PPC, Hansen BE, Stoop HJA, Peppelenbosch MP, van Eijck CH, Sleijfer S, Kwekkeboom J, Bruno MJ.

Int J Cancer. 2017 Aug 1;141(3):572-582. doi: 10.1002/ijc.30760. Epub 2017 May 19.

PMID:
28470686
15.

Low Tumor Mitochondrial DNA Content Is Associated with Better Outcome in Breast Cancer Patients Receiving Anthracycline-Based Chemotherapy.

Weerts MJA, Hollestelle A, Sieuwerts AM, Foekens JA, Sleijfer S, Martens JWM.

Clin Cancer Res. 2017 Aug 15;23(16):4735-4743. doi: 10.1158/1078-0432.CCR-17-0032. Epub 2017 Apr 18.

PMID:
28420722
16.

Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels.

Casali PG, Zalcberg J, Le Cesne A, Reichardt P, Blay JY, Lindner LH, Judson IR, Schöffski P, Leyvraz S, Italiano A, Grünwald V, Pousa AL, Kotasek D, Sleijfer S, Kerst JM, Rutkowski P, Fumagalli E, Hogendoorn P, Litière S, Marreaud S, van der Graaf W, Gronchi A, Verweij J; European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group.

J Clin Oncol. 2017 May 20;35(15):1713-1720. doi: 10.1200/JCO.2016.71.0228. Epub 2017 Mar 31.

PMID:
28362562
17.

PD-L1, Galectin-9 and CD8+ tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma.

Sideras K, Biermann K, Verheij J, Takkenberg BR, Mancham S, Hansen BE, Schutz HM, de Man RA, Sprengers D, Buschow SI, Verseput MC, Boor PP, Pan Q, van Gulik TM, Terkivatan T, Ijzermans JN, Beuers UH, Sleijfer S, Bruno MJ, Kwekkeboom J.

Oncoimmunology. 2017 Jan 3;6(2):e1273309. doi: 10.1080/2162402X.2016.1273309. eCollection 2017.

18.

Identification of microRNA biomarkers for response of advanced soft tissue sarcomas to eribulin: Translational results of the EORTC 62052 trial.

Wiemer EAC, Wozniak A, Burger H, Smid M, Floris G, Nzokirantevye A, Sciot R, Sleijfer S, Schöffski P.

Eur J Cancer. 2017 Apr;75:33-40. doi: 10.1016/j.ejca.2016.12.018. Epub 2017 Feb 16.

PMID:
28214655
19.

Application of circulating tumor DNA in prospective clinical oncology trials - standardization of preanalytical conditions.

van Dessel LF, Beije N, Helmijr JC, Vitale SR, Kraan J, Look MP, de Wit R, Sleijfer S, Jansen MP, Martens JW, Lolkema MP.

Mol Oncol. 2017 Mar;11(3):295-304. doi: 10.1002/1878-0261.12037. Epub 2017 Feb 22.

20.

Central venous access related adverse events after trabectedin infusions in soft tissue sarcoma patients; experience and management in a nationwide multi-center study.

Verboom MC, Ouwerkerk J, Steeghs N, Lutjeboer J, Martijn Kerst J, van der Graaf WTA, Reyners AKL, Sleijfer S, Gelderblom H.

Clin Sarcoma Res. 2017 Jan 31;7:2. doi: 10.1186/s13569-017-0066-6. eCollection 2017.

Supplemental Content

Loading ...
Support Center